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Abstract: Osteoarthritis is a degenerative disease that strongly correlates with age and promotes
the breakdown of joint cartilage and subchondral bone. There has been a surge of interest in
developing cell-based therapies, focused particularly on the use of mesenchymal stromal cells (MSCs)
isolated from adult tissues. It seems that MSCs derived from synovial joint tissues exhibit superior
chondrogenic ability, but their unclear distribution and low frequency actually limit their clinical
application. To date, the influence of aging on synovial joint derived MSCs’ biological characteristics
and differentiation abilities remains unknown, and a full understanding of the mechanisms involved in
cellular aging is lacking. The aim of this study was therefore to investigate the presence of age-related
alterations in synovial fluid MSCs and their influence on the potential ability of MSCs to differentiate
toward chondrogenic phenotypes. Synovial fluid MSCs, isolated from healthy equine donors from
3 to 40 years old, were cultured in vitro and stimulated towards chondrogenic differentiation for
up to 21 days. An equine model was chosen due to the high degree of similarity of the anatomy
of the knee joint to the human knee joint and as spontaneous disorders develop that are clinically
relevant to similar human disorders. The results showed a reduction in cell proliferation correlated
with age and the presence of age-related tetraploid cells. Ultrastructural analysis demonstrated
the presence of morphological features correlated with aging such as endoplasmic reticulum stress,
autophagy, and mitophagy. Alcian blue assay and real-time PCR data showed a reduction of efficiency
in the chondrogenic differentiation of aged synovial fluid MSCs compared to young MSCs. All these
data highlighted the influence of aging on MSCs’ characteristics and ability to differentiate towards
chondrogenic differentiation and emphasize the importance of considering age-related alterations of
MSCs in clinical applications.
Keywords: aging; senescence; MSCs; chondrogenic differentiation; osteoarthritis
1. Introduction
Many joint disorders, such as osteoarthritis, can lead to cartilage defects. Articular cartilage shows
limited regenerative potential because of its avascular nature and due to its paucity of mesenchymal
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stromal cells (MSCs). For this reason, articular cartilage defects remain a real challenge in the field of
regenerative medicine [1]. A great deal of effort has been made regarding cell therapy based on the use of
MSCs, often in combination with biomaterials, in order to improve tissue regeneration. Currently, MSCs
still represent a good candidate for tissue repair and regeneration [2,3]. MSCs or mesenchymal progenitor
cells can be defined as non-hematopoietic, self-renewing cells that can be expanded ex vivo and induced
to terminally differentiate, under certain conditions, into cells of mesenchymal lineage, including
osteoblasts [4,5], chondrocytes [6–8], adipocytes [9], and hematopoietic-supporting stroma [10].
Adult MSCs are localized in a special microenvironment, called the “niche”, that provides
homeostasis, proliferative control, and the maintenance of cell number [11]. Since their first isolation
from bone marrow [12,13], MSCs have been described in several other tissues, both from adult and
fetal tissues, such as adipose tissue [14], dental pulp [15], periosteum [16,17], the umbilical cord [18,19],
human synovial membrane (SmMSCs) [20], as well as in synovial fluid (synovial fluid mesenchymal
stromal cells (SfMSCs)) [1].
MSCs from different tissues have been shown to differ dramatically in their chondrogenic potency.
Actually, it is considered that SfMSCs exhibit a superior chondrogenic ability compared with those derived
from non-joint tissues [1]. The immunophenotype of SfMSC recapitulates a typical mesenchymal profile
and displays a positive expression of CD105, CD90, and CD44, and the cells are negative for CD45 [21].
They are capable of differentiating into chondrocytes, osteoblasts, and adipocytes [22]. The numbers of
SfMSCs from anterior cruciate ligament injury patients were 100 times higher than those from healthy
knees [23], and their number also increased in knees with degenerated cartilage and osteoarthritis [22–24].
Although a growing body of research suggests that SfMSCs and SmMSCs represent a promising stem cell
source for osteochondral repair, only a few experimental studies have demonstrated that SmMSCs can be
effective in resurfacing full-thickness [25] or partial-thickness cartilage defects in rabbits [26]. Additionally,
only a few papers have been published to date demonstrating the presence and the multipotence of
SfMSCs isolated from the synovial fluid of normal and pathological horse joints [27].
Despite several powerful applications of MSCs in regenerative medicine, their features and
proprieties can be strongly influenced by several factors, such as aging. Aging is a complex process that
affects most of the biological functions, generally ending in diseases and death, due to the accumulation
of different types of stress [28]. MSCs isolated from young and elderly individuals have been shown
to have different properties, such as a reduction of colony forming efficiency, proliferative ability,
and osteogenic potential [29]. Indeed, multiple influences of age on stem cell function have been
confirmed, including effects on stem cell number, proliferation potential, senescence and apoptosis,
replicative capacity, and in vitro differentiation potential [30]. MSCs isolated from adipose tissue have
exhibited a donor’s age influence on replicative senescence, leading to cell apoptosis [31]. Furthermore,
it was demonstrated that chondrogenic and osteogenic plasticity were strongly age-related, in a
different manner to adipogenic and neurogenic plasticity [31]. On the contrary, dermal fibroblasts
display a steady proliferative potential that is totally independent of donor age [32].
Considering the presence of contradictory information regarding the influence of aging on MSCs’
biological performance and the importance of examining their proprieties to develop relevant stem cell
therapeutic strategies for regenerative medicine, the aim of this study is to investigate the age-related
influence on synovial fluid MSC phenotypes and on their in vitro chondrogenic differentiation potential.
SfMSCs were isolated from healthy tibio–tarsal joints of horses ranging from 3 to 40 years old,
and they were cultured in vitro and characterized for cell proliferation assay, cell cycle analysis, actin F
protein staining, and ultrastructure analysis with the aim of highlighting the presence of age-related
alterations. To evaluate the influence of aging on chondrogenic differentiation, SfMSCs were stimulated
in vitro for up to 21 days with chondrogenic factors, the expression of chondrogenic markers was
determined, and an Alcian blue staining assay was conducted.
An equine model was chosen due to the high similarity of the anatomy and the biomechanics
to the human knee joint. Moreover, horses suffer from cartilage injuries and joint diseases such as
osteoarthritis and osteochondrosis that are clinically relevant to similar human disorders [33].
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2. Materials and Methods
2.1. Isolation of Equine SfMSCs
Sample collection procedures were approved by the ethical committee of the University of Teramo
(3/10/2018) and by the Italian Ministry of Health (approval No. 0018640-P-2/0772018). After obtaining
the informed consent from the owners, synovial fluid (Sf) was aseptically collected from healthy
tibio–tarsal joints of horses ranging from 3 to 40 years old. The age, breed, sex, and the number of
samples are summarized in Table 1. Samples were collected in four groups, depending on age: 3 years
old (3Y), 12 years old (12Y), 23 years old (23Y), and 40 years old (40Y). The presence of any joint disease
was previously ruled out by means of clinical and radiographical examination. A minimum of 5 mL
of clear and blood-free Sf was obtained from each tibio–tarsal joint. Sf was diluted with phosphate
buffered saline (PBS) up to five volumes and was subsequently filtered through a 70 µm nylon filter
(Cell Strainer, BD Falcon, Leipzig, Germany) to remove debris and centrifuged at 160 g for 5 min at
room temperature (RT).
Table 1. Profiles of Sf samples obtained from the joints of horses of different ages.
Breed Age (Years) Gender Donor’s Number
1 Standardbred 3 M 4
2 Standardbred 12 F 2
3 Pleasure riding horse 12 M 1
4 Standardbred 23 F 3
5 Pleasure riding horse 40 M 2
The pellets were resuspended in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies,
Monza, Italy), supplemented with 10% fetal bovine serum (FBS, Life Technologies, Monza, Italy),
and plated in a 25 cm2 culture flask, at 37 ◦C in 5% CO2 for 7 days. Cells adhering to the bottom of the
flask were subsequently detached and cultured in the same conditions. Briefly, cells from passage 1 to
passage 6 were utilized for the all the experiments of the study.
2.2. mRNA Expression of Mesenchymal and Self-Renewal Markers by RT-PCR and Real-Time PCR
Total RNA was obtained with an RNeasy Mini Kit (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA) starting from cellular pellets, and 100 ng of total RNA was reverse transcribed into first-strand
cDNA using SuperScript™ III One-Step RT-PCR System (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). The PCR was performed by Phusion Green Hot Start II High-Fidelity DNA Polymerase kit
(Thermo Fisher Scientific, Waltham, MA, USA). Equine glyceraldehyde-3-phosphate dehydrogenase
gene (GAPDH) was used as a housekeeping gene for amplification control during the PCR assay.
The primer sequences were designed by Primer design Software (Primer3-based OligoPerfect, Thermo
Fisher Scientific, Waltham, MA, USA). The amplified DNA was then electrophoresed on a 2% agarose
gel and visualized by ethidium bromide staining; images were acquired by Image Station 2000R
(Kodak, NY, USA). The primer sequences used are shown in Table 2.
Table 2. Real-Time PCR primer sequences.
Name Forward Reverse bp
CD90 5′-ATGAGAATACCACCGCCACA-3′ 5′-AGTTTGTCTCGGAGCACAGA-3′ 262
CD105 5′-TCAGGTCCCCAACACTAACC-3′ 5′-AGTCTTGTTCGTGCTGAGGA-3′ 148
CD34 5′-CCTTGCCCAGTCTGAGGTTA-3′ 5′-GTCTTGCGGGAATAGTGCTG-3′ 172
SOX9 5′-GAACAGCCCGTCTACACACA-3′ 5′-GCCACTGATTCGCAACAAGG-3′ 235
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Table 2. Cont.
Name Forward Reverse bp
COLL2 5′-CTGGCAAGCAAGGAGACAGA-3′ 5′-CCATTAGCGCCATCTTTGCC-3′ 292
ACAN 5′-TCATCTAGAGCCCACTGCCT-3′ 5′-AGTCCACCGAGGTCCTCTAC-3′ 234
NANOG 5′-TCTCTCCTCTGCCTTCCTCC -3′ 5′-TCTGCTGGAGGCTGAGGTAT-3′ 225
OCT4 5′-GGTACGAGTGTGGTTCTGCA-3′ 5′-ACCGAGGAGTACAGCGTAGT-3′ 192
SOX2 5′-GCCCTGCAGTACAACTCCAT-3′ 5′-GACTTGACCACCGAACCCAT-3′ 128
GAPDH 5′-TGCCCCAATGTTTGTGATGG-3′ 5′-CACTGTGGTCATGAGTCCCT-3′ 154
For mRNA quantification, a Powerup SYBR master mix kit (Life Technologies, Thermo Fischer
Scientific, Monza, Italy) was used in combination with the specific primers shown in Table 2. Relative
gene expression levels were normalized to those of equine glyceraldehyde 3-phosphate dehydrogenase.
Data are presented as fold changes relative to levels of the reference sample by using formula 2−∆∆CT,
as recommended by the manufacturer (User Bulletin number 2 P/N 4303859; Applied Biosystems,
Waltham, MA, USA) The results were expressed as fold changes compared to a reference control group
made of a pool four healthy equine subjects, each 3 years old.
2.3. BrdU Proliferation Assay
Cell proliferation was assayed by BrdU assay kit (Roche, Basel, Switzerland) according to the
manufacturer’s instructions. Briefly, cells were seeded into a 96-well culture plate with DMEM
containing 10% FBS, 1% penicillin and streptomycin, and 1% fungizone in a density of 104 cells/well.
After 24 h, the medium was changed to a fresh one containing 10 µM BrdU for 12 h at 37 ◦C. After
the removal of the labeling solution, cells were fixed and incubated with anti-BrdU conjugated with
peroxidase antibody for 90 min at RT. After three washing steps in PBS, a tetramethyl-benzidine
(TMB) substrate solution was added for 10 min at RT, and the reaction was stopped with 1 M
H2SO4. The optical density was measured using a spectrophotometer microplate reader (Model680,
BioradLab Inc., CA, USA) at a wavelength of 450 nm and a reference wavelength of 690 nm.
Data from SfMSCs isolated from the groups of 12Y, 23Y, and 40Y were expressed as the percentage
of relative proliferation compared to SfMSCs isolated from a pool of four different healthy equine
subjects, each 3 years old (reference control group).
2.4. Cell Cycle Analysis
The flow cytometric analysis of the cell cycle was performed using propidium iodide (PI)/RNase
A staining according to standard procedures, as described previously [34]. Briefly, the SfMSCs were
detached from the surface of the flask with enzyme digestion for 3 min at room temperature, and then
collected and centrifuged at 300 g for 5 min. The pellets were resuspended in PBS and counted by
a hemocytometer. A total of 2.5 × 105 cells was centrifuged and then resuspended in ethanol 70%
overnight at−20 ◦C. Cells were then centrifuged at 300 g for 5 min, and the pellets obtained were washed
twice in PBS and resuspended in a solution of propidium iodide for at least 30 min. Samples were
analyzed on a FC500 flow cytometer (Beckman Coulter, Indianapolis, IN, USA) with the appropriate
software (version 2.2, CXP, Beckman Coulter). At least 15,000 events per sample were acquired.
2.5. Doubling Time Assay
SfMSCs isolated from all donors were seeded at the density of 5 × 103 cells/cm2 in 25 cm2 flasks
and allowed to grow until reaching 90% of confluence. At this point, cells were detached with enzyme
digestion, counted by automated cell countess (Countess™ Automated Cell Counter, Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA) and reseeded at passage P1 at the same density as
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previously described. The procedure was repeated from passage P1 to P4. Cell-doubling time (DT)
was calculated from counts for each passage according to the following two formulae [34]:
CD = ln(Nf/Ni)/ln(2)
DT = CT/CD
where Nf and Ni are the final and initial number of cells, respectively, and CT is the cell incubation
time expressed in days.
2.6. F-Actin Staining
F-actin protein was labeled by fluorescent phallotoxin, a bicyclic peptide showing a high
binding affinity toward actin small filament. The staining procedure was performed according to
the manufacturer’s instructions (Molecular Probes, Invitrogen, Eugene, OR, USA). Briefly, for each
sample, 2 × 105 cells were seeded on cover glasses in MEM supplemented with 10% FBS at 37 ◦C for
24 h. Then, samples were fixed in 4% paraformaldehyde in PBS for 20 min at 4 ◦C and subsequently
permeabilized by 0.1% Triton-X in PBS for 5 min at RT. Coverslips were stained with fluorescent
phallotoxin diluted to 1:40 in 1% bovine serum albumin (BSA) for 20 min at RT. After three washes in PBS
and distilled water, coverslips were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and then
mounted with the permanent mountant ProLong gold (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). Images were acquired by the fluorescence microscope Eclipse E800 (Nikon, Tokyo, Japan).
The quantitative analysis of phallotoxin-stained areas was assessed by area, counting five
fields for each of the three slides per sample at 60× magnification by the Leica Qwin 3.0 software
(Leica Microsystems Srl, Cambridge, UK), which allowed the phallotoxin-stained area to be selected
and measured.
2.7. TEM Analysis
Monolayers of equine SfMSCs were fixed with 2.5% (v/v) glutaraldehyde in 0.1 M cacodylate
buffer for 2 h at 4 ◦C and post-fixed with a solution of 1% osmium tetroxide in 0.1 M cacodylate buffer.
The cells were then embedded in epoxy resins after a graded-acetone serial dehydration step. Ultrathin
slices of 100 nm were stained by uranyl acetate solution and lead citrate and then observed with a
transmission electron microscope, CM10 Philips (FEI Company, Eindhoven, The Netherlands), at an
accelerating voltage of 80 kV. Images were recorded by Megaview III digital camera (FEI Company,
Eindhoven, The Netherlands).
2.8. Alcian Blue
SfMSCs isolated from all donors were seeded into a 6-well culture plate with DMEM containing
10% FBS, 1% penicillin and streptomycin, and 1% fungizone in a density of 105 cells/well. After 24 h,
the medium was changed with chondrogenic medium consisting of MEM supplemented with 2%
FBS, 100 nM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL ascorbate-2-phosphate
(Sigma-Aldrich, St. Louis, MO, USA), ITS (6.25 µg/mL insulin, 6.25 µg/ mL transferrin, 6.25 µg/mL
selenous acid) (Gibco, Thermo Fisher Scientific, Monza, Italy), and 10 ng/mL of transforming growth
factorβ3 (TGF-β3) (Millipore, Milan, Italy) for 21 days at 37 ◦C and 5% CO2. Chondrogenic differentiation
was induced up to 21 days, changing the medium every three days. At the end of the treatment, cells
were immediately fixed in 4% formaldehyde in phosphate buffer (PBS) for 4 h at 4 ◦C and then processed
for the Alcian blue staining procedure with an Alcian blue staining kit (Bio-Optica, Milan, Italy). Images
were acquired by the light microscope Eclipse E800 (Nikon, Tokyo, Japan).
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2.9. Chondrogenic Differentiation
SfMSCs were cultured in Dulbecco’s modified eagle medium (DMEM), supplemented with 10%
fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), and then they were grown into 3D cultures
as micromasses. Briefly, 2.5 × 105 cells were pelleted (10 min, 160 g) per tube (Sarstedt, Neumbrecht,
Germany) and kept in 1 mL chondrogenic medium consisting of MEM supplemented with 2% FBS,
100 nM dexamethasone (Sigma-Aldrich, St. Louis, Missouri, USA), 100 µg/mL ascorbate-2-phosphate
(Sigma-Aldrich, St. Louis, Missouri, USA), ITS (6.25 µg/mL insulin, 6.25 µg/ mL transferrin, 6.25 µg/mL
selenous acid) (Gibco, Thermo Fisher Scientific, Monza, Italy), and 10 ng/mL of TGF-β3 (Millipore,
Milan, Italy) for 21 days at 37 ◦C and 5% CO2. Control samples consisted of SfMSCs cultured in a
micromass system in MEM supplemented with 2% FBS for up to 21 days. At the end of each treatment,
cells were collected and RNA was extracted for quantitative real-time PCR (qRT-PCR) to evaluate the
expression of SOX9, COLL2, and ACAN chondrogenic markers.
2.10. Real-Time PCR
The chondrogenic mRNA marker expression was analyzed via real-time PCR (7500 Applied
Biosystems, Life Technologies, Monza, Italy). For mRNA quantification, the Powerup SYBR master
mix kit (Life Technologies, Thermo Fischer Scientific, Monza Italy) was used in combination with the
specific primers for the chondrogenic markers shown in Table 2. Relative gene expression levels were
normalized to those of equine glyceraldehyde 3-phosphate dehydrogenase. Data are presented as
fold changes relative to levels of the reference sample by using formula 2−∆∆CT, as recommended
by the manufacturer (User Bulletin number 2 P/N 4303859; Applied Biosystems). The quantitative
analysis of mRNA expression was performed in triplicate for each donor. The results were expressed
as fold changes compared to a reference control group made of a pool of four healthy equine subjects,
each 3 years old.
2.11. Statistical Analysis
Statistical analysis was carried out using GRAPH PAD PRISM 5.0 software (San Diego, CA, USA)
applying a one-way ANOVA followed by Tukey’s multiple comparison test. The differences were
considered significant at p < 0.05.
3. Results
With the primary aim of demonstrating the presence of age-associated features in SfMSCs isolated
from equine donors of different ages, experiments analyzing the mRNA expression of mesenchymal
and self-renewal markers—cell proliferation, cell cycle, cell surface area, actin distribution, and cell
ultrastructure—were carried out. Our data showed the presence of age-related features that could
interfere with the biological proprieties of SfMSCs. Following the preliminary results, to demonstrate
an age-related ability of SfMSCs to differentiate toward chondrogenic phenotypes, the expression of
mRNA chondrogenic markers and the deposition of proteoglycans were analyzed after 21 days of
in vitro stimulation with chondrogenic factors.
3.1. Mesenchymal and Self-Renewal Expression Markers
In order to demonstrate the mesenchymal phenotype of SfMSCs, the expressions of CD105, CD90,
and CD34 markers were investigated in agreement with the minimal criteria of the International Society
of Cellular Therapy (ISCT) [35]. Furthermore, the SfMSCs were further characterized by evaluating
the expression of self-renewal markers, such as homeobox protein transcription factor (NANOG),
octamer-binding transcription factor 4 (OCT4), and SRY (sex determining region Y)-box 2 (SOX2) genes [36].
A few days after primary culture, SfMSCs isolated from equine donors of 3Y, 12Y, 23Y, and 40Y
groups adhered to plastic culture flasks. RT-PCR analysis showed a positive expression for CD105 and
CD90 cell surface markers and a negative expression for the hematopoietic marker CD34 (Figure 1A).
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Real-time PCR data showed that the relative quantifications of the mRNAs of CD90 (Figure 1B)
and CD105 (Figure 1C) were not statistically different in all the samples analyzed, suggesting a
lack of a relationship between a donor’s age and the quantitative expression of the mesenchymal
stromal markers.
Regarding self-renewal markers, all the isolated SfMSCs were positive for NANOG, OCT4, and
SOX2 mRNA expression (Figure 2A), suggesting no influence of aging on multipotency markers. More
precisely, quantitative analysis by real-time PCR showed the lack of any significant difference regarding
the mRNA expression of OCT4 in all the samples tested (Figure 2B), while the mRNA expression of
NANOG and SOX2 was upregulated in the 40Y group compared to 3Y and 12Y (Figure 2C,D).
Figure 1. (A) RT-PCR analysis showing a positive expression of CD105 and CD90 and a negative
expression of CD34 mesenchymal stromal surface markers in synovial fluid mesenchymal stromal
cells (SfMSCs) cultured from equine donors of different ages: 3Y (3 years old), 12Y (12 years old),
23Y (23 years old), and 40Y (40 years old). Representative images of three independent experiments;
(B) real-time PCR data showing the quantitative expression of CD90 mRNA. The value corresponding
to each single donor and the mean level inside each group (black line) was reported. (C) Real-time PCR
data showing the quantitative expression of CD105 mRNA. The value corresponding to each single
donor and the mean level inside each group (black line) was reported. The values are represented as
fold increases related to a reference control consisting of a pool of four different healthy equine subjects,
each 3 years old. No statistical differences were observed between groups.
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Figure 2. (A) RT-PCR analysis showing a positive expression of NANOG, OCT4, and SOX2 self-renewal
markers in SfMSCs cultured from equine donors of different ages: 3Y (3 years old), 12Y (12 years old),
23Y (23 years old), and 40Y (40 years old). Representative images of three independent experiments;
(B) real-time PCR data showing the quantitative expression of NANOG mRNA in each single donor
and the mean level inside each group (black line). No statistical differences were observed between
groups. (C) Real-time PCR data showing the quantitative expression of NANOG mRNA in each single
donor and the mean level inside each group (black line). * represents a significant difference between
the 12Y and 40Y group; p < 0.05. # represents a significant difference between the 3Y and 40Y group;
p < 0.05. (D) Real-time PCR data showing the quantitative expression of SOX2 mRNA in each single
donor and the mean level inside each group (black line). * represents a significant difference between
the 3Y and 40Y group; p < 0.05. # represents a significant difference between the 12Y and 40Y group;
p < 0.05.
The values are represented as fold increases related to a reference control group consisting of a
pool of four different healthy equine subjects, each 3 years old.
3.2. SfMSCs Proliferation Assay
A stable arrest of the cell cycle is one of the hallmarks of aging [37]. In order to investigate the
alterations in age-related cell proliferation, a BrdU assay was carried out.
Results showed a reduction in BrdU incorporation, during the S-phase of the cell cycle, in SfMSCs
isolated in equine donors of 12Y, 23Y, and 40Y groups compared to young donors (3Y) (Figure 3).
No significant age-related arrest of the BrdU incorporation was detected in any sample.
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Figure 3. BrdU cell proliferation assay of equine SfMSCs cultured from donors at different ages. The
values of each donor and the mean value (black line) inside each group are represented. All the data
are expressed as percentages of relative amounts to a reference control group consisting of a pool of
four different healthy equine subjects, each 3 years old. * represents a significant difference between 3Y
and 12Y groups; p < 0.05. # represents a significant difference between 3Y and 22Y groups; p < 0.05. §
represents a significant difference between 3Y and 40Y groups; p < 0.05.
3.3. Cell Cycle Analysis
In order to better visualize any difference in the cell cycle, propidium iodide (PI) staining followed
by flow cytometry analysis was carried out.
The flow cytometry analysis of PI-stained cells showed a moderate percentage increase of cells in
the G0/G1 phase of the cell cycle, in a slightly age-dependent manner (Figure 4 and Table 3), in line
with the reduction of proliferation rates already seen in the BrdU proliferation assay. Interestingly,
these analyses also outlined an accumulation of tetraploid cells in all samples tested, and this feature
was observed with an age-dependent increase in the percentage of tetraploid cells, ranging from 7.6%
in young donors (3Y) to 14.4% in old donors (40Y) (Figure 4 A, Table 3 and Figure 4B).
In order to better define the role of the cell cycle in senescence and aged cells, the doubling time
assay was performed in SfMSCs derived from donors at different ages. The results showed a significant
difference of the doubling time in SfMSCs cultured from 40Y donors (Figure 5) compared to 3Y and
12Y donors, in agreement with the previous results of the BrdU proliferation assay and flow cytometric
analysis. However, the significant difference between the groups was observed only at passage 4 (p4).
Figure 4. Cont.
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Figure 4. (A) Representative results of the cell cycle distribution of SfMSCs isolated from donors of
different ages and measured by flow cytometry using propidium iodide staining. The percentage of
the cell cycle the phase is shown in a bar graph form. A moderate gain of cells in the G0/G1 phase
and a decrease of cells in S phase is observed when comparing the 3Y group with the 40Y group.
An increasing number of age-related tetraploid cells is observed. Number of events: cell frequency;
propidium iodide: DNA staining fluorochrome. (B) Representative light microscope images of in vitro
SfMSCs isolated from a 3-year-old equine donor showing the presence of tetraploid cells (white arrow)
(bar: 30 µm). (C) Representative light microscope image of in vitro SfMSCs isolated from a 40-year-old
equine donor showing the presence of tetraploid cells (white arrows) (bar: 30 µm).
Table 3. Flow cytometry data of cell cycle distribution and frequency of tetraploid cells (4N) in SfMSCs
isolated from equine donors of different ages.Values corresponding to each equine donor are reported
and organized in the experimental group associated with age. The experiment was repeated in triplicate
for each donor, and the results are expressed as percentage ± SD. a represents a significant difference
from 40Y group; p < 0.05.
G0/G1 (%) S Phase (%) G2/M (%) 4N (%)
3Y Group
Donor 1 56.6 ± 1.2 5.3 ± 2.6 28.6 ± 1.4 8.6 ± 1.2 a
Donor 2 58.0 ± 1.1 9.7 ± 1.4 26.9 ± 1.6 7.5 ± 0.9 a
Donor 3 58.5 ± 1.4 21.3 ± 0.9 18.3 ± 1.1 7.4 ± 0.9 a
Donor 4 48.6 ± 0.8 15.0 ± 0.5 28.2 ± 0.9 7.6 ± 0.3 a
12Y Group
Donor 1 64.1 ± 1.6 10.1 ± 1.1 23.3 ± 1.4 12.0 ± 1.2
Donor 2 65.6 ± 1.6 9.5 ± 1.5 23.3 ± 1.1 8.5 ± 0.9
Donor 3 59.9 ± 1.7 9.0 ± 1.6 22.6 ± 1.2 8.2 ± 0.5
23Y Group
Donor 1 68.7 ± 1.6 4.9 ± 0.9 25.5 ± 1.4 10.5 ± 0.6
Donor 2 61.6 ± 0.5 9.4 ± 0.2 16.5 ± 0.6 9.5 ± 0.3
Donor 3 84.7 ± 0.8 7.8 ± 0.3 5.2 ± 0.7 10.7 ± 0.3
40Y Group
Donor 1 67.1 ± 1.1 9.9 ± 1.5 18.9 ± 1.2 14.4 ± 0.7
Donor 2 74.3 ± 1.2 8.1 ± 2.4 16.1 ± 1.5 18.5 ± 1.1
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Figure 5. Doubling time for SfMSCs isolated from equine donors of different ages and cultured in vitro
from passage 0 (P0) to passage 4 (P4). Values corresponding to each donor and the mean value
(colored line) corresponding to each age-related group are reported. * represents a significant difference
between 3Y and 40Y groups; p < 0.05. # represents a significant difference between 12Y and 40Y groups
at P4; p < 0.05.
3.4. F-Actin Staining
Since senescent cells stop dividing, they have significant alterations in their motility and strength,
which reflect morphological changes due to a lack of integrity in the cytoskeleton. In order to
demonstrate morphological changes connected with the expression and distribution of cytoskeleton
proteins, the status of actin fibers in relation to the shape and size of cells was analyzed by phalloidin
staining assay. Results showed the presence of several actin fibers, which are parallel-oriented in
cells isolated from donors of 3-year-olds (3Y) (Figure 6A). A similar distribution and localization was
observed in samples obtained from equine donors of 12 years of age (12Y) (Figure 6B), while a less
regular orientation was detected in cells from equine donors of 23 years (23Y) (Figure 6C) and 40 years
of age (40Y) (Figure 6D). In the latter sample, actin fibers showed a more random distribution, in
combination with an enlarged cell size and irregular shape (Figure 6D).
Since the cell surface area is one of the most pronounced morphological changes occurring in
senescent cells, a quantitative analysis of the cellular area stained by the phalloidin probe was carried
out. The results demonstrated an increase of cell surface area in SfMSCs isolated from the old donors
(40Y) compared to young associated donors (3Y), confirming a relationship of the cell surface area with
aging (Figure 6E).
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Figure 6. Fluorescence microscopy images of the phalloidin staining assay demonstrating the presence
and distribution of actin fibers (red color; arrows) in equine SfMSCs isolated from donors of different
ages. Nuclei were counterstained with DAPI (blue color). All the images have a magnification of 600×
and are representative of three independent experiments. (A) SfMSCs isolated from equine donors
of 3 years of age; (B) SfMSCs isolated from equine donors of 12 years of age; (C) SfMSCs isolated
from equine donors of 23 years of age; (D) SfMSCs isolated from equine donors of 40 years of age.
(E) Quantitative analysis of the cell surface area of equine SfMSCs isolated from donors at different
ages and stained with phalloidin probe. Values corresponding to each donor and the mean value (line)
corresponding to each age-related group are represented. * represents a significant difference between
3Y and 40Y groups; p < 0.05.
3.5. Ultrastructural Analysis of Equine SfMSCs
To better evaluate the morphological changes associated with aging, an ultrastructural analysis by
TEM was carried out.
Equine SfMSCs isolated from 3Y equine donors showed a round-shaped nucleus, with three or
more well preserved nucleoli (Figure 7A). At low magnification, the cytoplasm appeared to be filled
by several black vacuoles, corresponding to secondary lysosomes, suggesting a strong degradation
activity (Figure 7A,B). At higher magnification, primary and secondary lysosomes were detected
(Figure 7B). Regular mitochondria and a widely developed Golgi complex were observed (Figure 7B).
An enlarged rough endoplasmic reticulum (RER) was detected, surrounding the nuclear envelope
(Figure 7A,B). In equine SfMSCs, isolated from equine donors of 12 years of age, a reduced number
of black vacuoles was observed (Figure 7C,D). At higher magnification, a few lysosomes and dilated
RER cisternae were detected (Figure 7D). Equine SfMSCs, isolated from equine donors of 23-year-olds,
showed a fibroblast-like shape, with a big nucleus and multiple nucleoli (Figure 7E). At higher
magnification, several primary lysosomes, regular mitochondria, and dilated RER were observed
(Figure 7F). Binucleated SfMSCs, corresponding to the tetraploid cells previously described, were
often observed in donors of 40-year-olds (Figure 7G). At higher magnification, a dilated RER, several
mitochondria, and several mitophagy vesicles were detected (Figure 7H).
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Figure 7. Representative images of the SfMSC ultrastructure. (A) Equine SfMSCs from a 3-year-old
donor, showing a polygonal shape, with a round nucleus (N) and several nucleoli (n). The cytoplasm is
characterized by the presence of several secondary lysosomes (white arrow) (bar: 10 µm). (B) Higher
magnification of equine SfMSCs from a 3-year-old donor. A Golgi complex (G), mitochondria (m) and
an enlarged rough endoplasmic reticulum (RER) are detected in the cytoplasm. Primary (arrowhead)
and secondary lysosomes (white arrow) are observed (bar: 100 nm). (C) Equine SfMSCs from a
12-year-old donor. Cells showed a well-preserved nucleus (N) and nucleoli (n) and a widely developed
RER, surrounding the nuclear envelope. There is a clear lack of secondary lysosomes (bar: 10 µm).
(D) Cytoplasm details of equine SfMSCs from a 12-year-old donor, in which a regular RER and enlarged
RER are clearly observed (bar: 1 µm). (E) Equine SfMSCs from a 23-year-old equine donor showing a
fibroblast-like shape, regular nucleus (N), and several nucleoli (n) (bar: 10 µm). (F) Higher magnification
of the cytoplasm of equine SfMSCs from a 23-year-old donor. Several primary lysosomes (arrowheads),
mitochondria (m), and dilated RER are observed (bar: 1 µm). (G) Binucleated SfMSCs, corresponding
to tetraploid cells, isolated from a 40-year-old equine donor showing a fibroblast-like shape, nucleus
(N), and several nucleoli (n) (bar: 5000 nm). (H) Detail of the cytoplasm in which several mitochondria
(m), a dilated RER, and mitophagy vesicles (*) are visible (bar: 1 µm).
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3.6. Chondrogenic Differentiation
In order to demonstrate the deposition of glycosaminoglycans (GAG) in the extracellular matrix of
SfMSCs, isolated from equine donors at different ages, the Alcian blue staining procedure was carried
out. Figure ??A shows the presence of an intense blue color in the extracellular matrix of SfMSCs
isolated from equine donors of 3 years of age and stimulated in vitro toward chondrogenic phenotypes
for up to 21 days (Figure ??A, D21 3Y). A gradual decrease of the color intensity was observed in
SfMSCs isolated from 12 and 22-year-old equine donors (Figure ??A). Samples obtained from equine
donors of 40 years of age did not show any kind of color, suggesting a low amount of GAG deposition
(Figure ??A).
To demonstrate a modified age-related ability of SfMSCs to differentiate toward chondrogenic
phenotypes, the expression of mRNA chondrogenic markers was analyzed after 21 days of in vitro
stimulation with chondrogenic factors.
In control samples of SfMSCs isolated from all donors, a low level of COLL2A mRNA was detected
(Figure ??B), while the level of COLL2A mRNA was consistently higher in 3-year-old equine SfMSCs
stimulated to chondrogenic differentiation for up to 21 days (Figure ??B). Furthermore, in chondrogenic
differentiated samples, COLL2A mRNA showed a strong age-related reduction (Figure ??B).
Regarding the transcription factor SOX9, real-time PCR data demonstrated a weak upregulation in
all the differentiated samples (Figure ??C) compared to their corresponding control groups, in agreement
with the long chondrogenic stimulation (21 days). However, the highest level of expression was
shown in the 3Y D21 group, followed by a decrease of the signal in all the other differentiated groups
(Figure ??C), suggesting age-related SOX9 mRNA expression.
SfMSCs showed a weak signal of ACAN mRNA in all the control groups (Figure ??D), while a
strong upregulation was detected in all the chondrogenic differentiated groups (Figure ??D). Similar
to SOX9 mRNA expression, the highest signal of ACAN mRNA expression was observed in the 3Y
D21 group, followed by a gradual reduction in all the other differentiated groups, suggesting an
age-dependent relationship of ACAN mRNA expression.
Figure 8. (A) Representative images of the Alcian blue staining assay showing the deposition of
glycosaminoglycans (GAG) in the extracellular matrix in SfMSCs, isolated from equine donors of
3-year-olds (3Y), 12-year-olds (12Y), 23-year-olds (23Y), and 40-year-olds (40Y) and stimulated toward
chondrogenic phenotypes for up to 21 days (scale bar: 30 µm). (B) Real-time PCR relative expression of
COLL2 mRNA in control (CTR) and differentiated (D21) SfMSCs toward chondrogenic phenotypes for
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up to 21 days. Values corresponding to each equine donor involved in the study and the mean value
(black line) of each experimental group (3Y, 12Y, 23Y, and 40Y) are shown. Values are represented as
fold increase related to a reference control group consisting of a pool of four different healthy equine
subjects, each 3 years old. * represents a significant difference between 3Y CTR and 3Y D21 groups;
p < 0.05. # represents a significant difference between 3Y D21 and 12Y D21 groups; p < 0.05. § represents
a significant difference between 3Y D21 and 23Y D21 groups; p < 0.05. §§ represents a significant
difference between 3Y D21 and 40Y D21 groups; p < 0.05. (C) Real-time PCR relative expression of
SOX9 mRNA in control (CTR) and differentiated (D21) SfMSCs toward chondrogenic phenotypes for
up to 21 days. Values corresponding to each equine donor involved in the study and the mean value
(black line) of each experimental group (3Y, 12Y, 23Y, and 40Y) are shown. Values are represented as
fold increase related to a reference control group consisting of a pool of four different healthy equine
subjects, each 3 years old. * represents a significant difference between 3Y D21 and 40Y D21 groups;
p < 0.05. (D) Real-time PCR relative expression of ACAN mRNA in control (CTR) and differentiated
(d21) SfMSCs toward chondrogenic phenotypes fir up to 21 days. Values corresponding to each equine
donor involved in the study and the mean value (black line) of each experimental group (3Y, 12Y,
22Y, and 40Y) are shown. Values are represented as fold increase related to a reference control group
consisting of a pool of four different healthy equine subjects, each 3 years old. P < 0.05. * represents a
significant difference between 3Y CTR and 3Y D21 groups; p < 0.05. # represents a significant difference
between 3Y D21 and 23Y D21 groups; p < 0.05. § represents a significant difference between 3Y D21
and 40Y D21 groups; p < 0.05.
4. Discussion
Osteoarthritis is a degenerative disease that strongly correlates with age [38,39]. Mesenchymal
stem/progenitor cells derived from synovial joint tissues exhibit a superior chondrogenic ability
compared with those derived from non-joint tissues [1,40,41]; thus, they represent the best choice
for the regeneration and repair of cartilage [40]. Nevertheless, aging can compromise the biological
proprieties of MSCs and their ability to differentiate into multiple cell types of the mesoderm germ
layer [29].
In this study, we focused our attention on equine SfMSCs and some age-related alterations, which
influence their tissue repair abilities. The main goal was to demonstrate the presence of an increasing
amount of age-related hallmarks in synovial fluid MSCs and their influence on the potential ability to
differentiate toward chondrogenic phenotypes.
Sfs from healthy equine donors of different ages were collected and MSCs were isolated according
to previous protocol [27]. We decided to base our study on an equine model due to the non-invasive
technique of synovial fluid collection and because horses represent a useful animal model of several
spontaneous disorders that are clinically relevant to similar human disorders [19]. Furthermore, joint
injuries are among the most common catastrophic injuries in thoroughbred racehorses, which are
mainly repaired by arthroscopic surgery [42].
All the SfMSCs tested in our study were positive for the mesenchymal cell surface markers CD90,
CD105, while they were negative for CD34 [19,35,43]. Furthermore, real-time PCR data demonstrated
the lack of significant quantitative differences in the expression of the CD90 and CD105 between
young and old donors, suggesting that there is no relationship between mesenchymal surface marker
expression and age. A similar trend was observed for the expression of multipotency markers. Sf-MSCs
isolated from equine donors of different ages were positive for OCT4, NANOG, and SOX2 mRNA
expression, suggesting that even healthy, age-derived MSCs keep their mesenchymal and self-renewal
phenotype. The lack of a quantitative difference in OCT4 mRNA expression confirms these results,
while an upregulation of NANOG and SOX2 mRNA expression was unexpectedly observed in
equine age-derived SfMSCs (40Y group). A few data are available regarding the variation of the
expression of cluster of differentiation markers and self-renewal markers related to aging in stem
cells [44,45]. Human MSCs isolated from adipose tissue express pluripotency markers over several
in vitro passages [37]. In addition, it has been demonstrated that a high level of NANOG and OCT4
Cells 2019, 8, 1116 16 of 20
protein expression in adult MSCs is essential for maintaining the self-renewal properties of MSCs [46].
All in all, our data demonstrate the lack of a relationship between the expression of mesenchymal stem
cells and multipotency markers with aging, and the ability to isolate adult stem cells even from healthy
aged donors. Although previous studies on age-related alterations of stem cells demonstrated stem
cell exhaustion as a hallmark of aging [44], this is not present in hematopoietic stem cells, which show
an increase in stem cell proliferation related to aging [38].
The BrdU cell proliferation assay showed a 50% reduction of cell proliferation in SfMSCs isolated
from 40-year-old horses compared to 3Y donors, suggesting the acquisition of a gradual senescent
phenotype, one of the most repetitive hallmarks of aging [38,44]. These results are confirmed by a
doubling time assay, which showed the highest time for cell doubling in the 40Y sample.
The flow cytometry analysis of equine SF-MSCs, surprisingly, demonstrated the presence of
tetraploid cells in all samples analyzed. However, the percentage increased with age, suggesting a
relationship between tetraploidy and aging. Although nearly all mammalian species are diploid, whole
genome duplications occur in select mammalian tissues as part of normal development [47]. In humans,
a programmed polyploidization has been described in the placenta [48], which can reach a DNA
content of up to 64 N. Megakaryocytes [49] and hepatocytes [50] become polyploid through abortive
mitosis, while in skeletal muscles and osteoclasts, cell fusion generates polynucleated terminally
differentiated cells [51]. To date, the benefit of programmed polyploidy is not fully understood.
However, the presence of tetraploid and/or octaploid cells in some tissues correlated with age or stress
conditions has been described [47,48]. The incidence of polyploidy increases with age in hepatocytes
and vascular smooth muscle cells [50,52], while cardiomyocytes under cardiac overloading and
hypertension [53] and hepatocytes under oxidative stress [54] showed a high level of polyploid cells.
The mechanisms and consequences of polyploidy in pathological situations are still unknown [47].
Estrada and colleagues have demonstrated the presence of a high percentage of aneuploid MSCs,
which progressively increase until senescence [55], proposing aneuploidy as a main cause of genetic
instability and replicative senescence and suggesting the assessment of aneuploidy before any clinical
use of MSCs.
Since senescent cells cease to divide and have marked changes in morphology, motility, and
mechanical strength, the integrity of cytoskeletons is expected to be modified [56]. Since actin stress
fiber is a key factor determining cell shape and motility, a change in its abundance and localization may
be causatively related to the enlarged and round shape as well as the decreased motility of senescent
cells [56]. By using phalloidin staining assay, a selective probe for F-actin, the presence and localization
of actin filaments has been investigated in aged equine SfMSCs. The results showed the presence of
parallel filaments in young SfMSCs, while a more irregular and intermingled disposition of actin fibers
was observed in aged SfMSCs. The resulting cellular shape was largely modified in age-derived cells
compared to young cells, changing from short spindle fusiform cells to a large flat spread. Moreover,
the cellular surface area greatly increased in age-derived MSCs, in agreement with previous studies
carried out on dermal age-derived MSCs, where the increase in the surface area was attributed in part
to changes in the cytoskeleton [57].
Alterations of subcellular organelles such as lysosomes, mitochondria, nuclei, and the endoplasmic
reticulum (ER) has been already described in senescent cells [56]. The ultrastructural analysis of
equine SfMSCs showed the presence of several autophagic vesicles, a widely dispersed endoplasmic
reticulum and Golgi complex, several lysosomes, and an autophagosome—all morphological features
connected with active stem cells, which require these functions to get rid of cellular waste produced
during their quiescent stage [58]. Autophagy is a highly conserved catabolic process whereby
intracellular components, such as protein, organelles, and cytoplasm, are delivered to lysosomes for
self-degradation. The final goal is to maintain cellular homeostasis under physiological and stress
conditions. Its activation promotes cellular survival by maintaining adequate metabolic functions,
bioenergetics levels, and an amino acid pool. Being a sensor of stress, autophagy has been linked to
aging [58]. Several studies on animal models [59] and human tissues, such as muscle and hematopoietic
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stem cells, support a decline in autophagic activity related to aging [58,60]. Our analysis demonstrated
a huge number of primary lysosomes and autophagosomes in the cytoplasm of youth-derived cells,
while they disappeared in cells isolated from donors of 40 years of age, confirming a decline of
autophagy activity during aging. Furthermore, ultrastructure observations demonstrated a widely
distributed RER inside the cytoplasm in youth-derived cells, suggesting an intense RER activity
connected with the maintenance of cellular homeostasis. On the contrary, age-derived cells showed a
dilated RER morphology, surrounded by a reduced number of ribosomes, suggesting the presence of
ER stress, as a consequence of an imbalance between ER protein folding loads and capacity, leading
to the accumulation of unfolded proteins in the ER lumen [61,62]. One counteraction to the cellular
microenvironment induced by ER stress is the activation of mitophagy, a particular kind of autophagy,
the aim of which is to destroy mitochondria and, in such a way, to protect against the release of
pro-apoptotic proteins, the generation of toxic reactive oxygen species (ROS), and the futile hydrolysis
of adenosine triphosphate (ATP) [63]. In our samples, ER stress, coupled to several mitophagosomes,
was distinctly observed only in SfMSCs isolated from equine donors of 40 years of age, confirming an
activation of mitochondrial autophagy in aged MSCs.
Aging can seriously compromise the ability of MSCs to differentiate in vitro towards osteogenic,
adipogenic, and chondrogenic phenotypes. With SfMSCs being more prone to chondrogenic
differentiation [40], we investigated the correlation between age-related SfMSCs and chondrogenic
ability. To this end, SfMSCs were stimulated in vitro toward chondrogenic differentiation for up to
21 days. Alcian blue staining assay and real-time PCR for chondrogenic markers showed a reduced
ability of SfMSCs, isolated from equine donors of 40 years of age, to differentiate toward chondrogenic
phenotypes, suggesting an impairment of chondrogenic differentiation in aged SfMSCs [64].
5. Conclusion
Differences in the characteristics of stem cells derived from donors of different ages can affect the
outcome of cell-based therapy [64].
In this study, SfMSCs did not show any significant alteration in their mesenchymal phenotype
and multipotency related to aging, suggesting an unmodified ability in their biological proprieties and
differentiation ability. Nevertheless, some senescence-related features such as cell growth, cell surface
area, and cell ultrastructure demonstrate gradual alterations connected with aging, which could take
part in the impairment of the functionality of MSCs. Indeed, our data demonstrate that the main feature
compromised by aging is the ability of SfMSCs to differentiate toward chondrogenic phenotypes,
which results in significantly downregulated chondrogenic markers in age-derived SfMSCs.
These results confirm that aging can significantly compromise MSCs’ characteristics and performance,
which should be taken into consideration in regenerative medicine based on MSC application.
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